

Cancer Prevention and Control CIRB Meeting Agenda

March 25, 2021

I. Continuing Review

A191901, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Protocol Version Date 11/09/20)

II. Continuing Review

A221602, Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial (Protocol Version Date 09/11/20)

III. Continuing Review

NRG-CC003, Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer (Protocol Version Date 06/15/20)

IV. Continuing Review

URCC-16092, Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients with Cancer (Protocol Version Date 04/22/20)

V. Continuing Review

WF-1805CD, Implementation and Effectiveness Trial of HN-STAR (Protocol Version Date 09/04/20)

VI. Continuing Review

WF-30917CD, A Stepped-Care Telehealth Approach to Treat Distress in Cancer Survivors (Protocol Version Date 12/09/20)

VII. New Study - Initial Review

URCC-19178, Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy (Protocol Version Date 02/05/21)

VIII. Amendment

NWU2015-06-01, Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention (Protocol Version Date 02/02/21)

IX. Study Site Response to Unanticipated Problem and Serious Noncompliance Review

A221701, Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment) (Protocol Version Date 08/14/20)
